A Study of LY4226695 in Healthy Participants

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date changed from estimate of Aug 2026 to Aug 27, 2026
    • Eligibility criteria expanded, about 13 words
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Eli Lilly
366 trials monitored
See 16 trials at risk
The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.
Trial Details
NCT Number NCT07767487
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Healthy
Enrollment 148 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov